Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;25(2):98-100.
doi: 10.5455/msm.2013.25.98-100.

Phytoestrogens Impact on Menopausal Symptomatology

Free PMC article

Phytoestrogens Impact on Menopausal Symptomatology

Semso Rosic et al. Mater Sociomed. .
Free PMC article


Conflict of interest: none declared.

Introduction: The balance of endocrine and autocrine activity usually starts to fade after age of 45 years in women. This is particularly true for the imbalance of estrogen and progesterone. This imbalance creates a number of clinical syndromes and disorders.

Goal: The goal of the study is to determine the effects of phytoestrogens on the psychological, somatic-vegetative and urogenital symptoms of menopause.

Material and methods: The study included 275 respondents who are more than three in menopause. Respondents were taking commercially available phytoestrogens, in duration of 12 months.

Results and discussion: Review of clinical and epidemiological studies showing different results regarding effects of phytoestrogens on menopausal symptoms. In our study there was a significant reduction of somatic-vegetative and psychological symptoms under the influence of phytoestrogens, while urogenital symptomatology was not significantly changed. We recommend the use of phytoestrogens in early postmenopausal women with moderate symptoms.

Keywords: menopausal symptoms; phytoestrogens.


Figure 1.
Figure 1.
Cattell slope model (MRS).
Figure 2.
Figure 2.
Percentage decrease in menopausal symptoms

Similar articles

See all similar articles

Cited by 3 articles


    1. Šimunić V. Klimakterij. Menopauza. Postmenopauza. U: Šimunić V. i sur. Ginekologija, Ljevak, 2011; 368-388
    1. Walker-Bone Cooper C. Epidemiology of the menopause. U: Agnusdei D. Corupston J. SERMs. London: M. Dunitz, 2000: 15-30
    1. Writing Group for the Women’s Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333 - PubMed
    1. Grady D, Herrington D, Bittner V, et al. , for thr HERS Research Group Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 49-57 - PubMed
    1. Million Women Study Collaborators Breast cancer and hormone-replacement in the Million Women Study. Lancet. 2003; 362: 419-427 - PubMed

LinkOut - more resources